About: Intensity Therapeutics, Inc., a late-stage clinical biotechnology company, engages in the provision of treatment for the regional and systemic nature of cancer relapse and metastasis in the United States. Its lead product candidate includes INT230-6, which is in Phase 3 clinical studies for the treatment of soft tissue sarcoma; and neoadjuvant and metastatic triple negative breast cancer which is in Phase 2 clinical trials. The company was incorporated in 2012 and is headquartered in Shelton, Connecticut.
Sector: Healthcare
Industry: Biotechnology
Latest price: $3.13 (-5.44%)
INTS NASDAQ Intensity Therapeutics, Inc. Common stock
Intensity Therapeutics, Inc. Common stock share price
INTS price activity
Last Price
$3.130
Change (24hr)
-0.18 USD (-5.44%)
Volume
2.98K
Volume (4w avg)
-
Open
$3.20
Day Range
$3.10 - $3.20
Previous Close
$3.31
Last Trade
13 Oct, 3:36 pm GMT+0
Delayed
13 Oct, 3:36 pm GMT+0
INTS price performance
Delayed
13 Oct, 3:36 pm GMT+0
INTS Market Signals